

ResistancePlus® GC

N. gonorrhoeae + ciprofloxacin susceptibility

Smarter Diagnostics. Simplified Patient Care.



Up to 70% of gonorrhoea infections could be treated with ciprofloxacin, a simple oral antibiotic.¹⁻⁴

- ▶ Guidelines for gonococcal infection (GC) management call to preserve ceftriaxone, recommending ciprofloxacin as an alternative when susceptibility information is available^{5,6}
- ▶ Personalise patient treatment based on antimicrobial resistance (AMR) status
- ▶ Boost utility of your existing GC testing workflows to provide key AMR information

ResistancePlus® GC is a single-well multiplex qPCR test for detection of *Neisseria gonorrhoeae* and *gyrA* markers linked to ciprofloxacin susceptibility.⁷⁻⁹ Dual *N. gonorrhoeae* targets, ciprofloxacin resistance and susceptibility targets offer pathogen detection and AMR determination. **ResistancePlus® GC** is validated for a range of specimen types¹⁰ and powered by proprietary **PlexPCR®** technologies demonstrating improved multiplex performance compared with other probe-based tests.¹¹

Single-well **PlexPCR®** test

Channel	Target
1	<i>N. gonorrhoeae</i> (<i>opa</i>)
2	<i>N. gonorrhoeae</i> (<i>porA</i>)
3	<i>gyrA</i> S91F mutation
4	<i>gyrA</i> S91 wild type
5	Internal Control

SpeedX Analysis for **ResistancePlus® GC**

Improve laboratory productivity with a validated software solution for automated result calling and simple data processing. Streamlined workflow to support rapid, routine diagnostics with audit trails and user traceability. Included in contract pricing and installed on a high security and GDPR compliant platform, with LIS compatibility.

Product	Compatible	Size	Cat#
ResistancePlus® GC*	LC480 II	100 reactions	2011001
		25 reactions	2011025
	ABI 7500/ 7500 Fast/Dx	100 reactions	2013001
		25 reactions	2013025
	CFX96 IVD/ CFX96 Touch	100 reactions	2015001
		25 reactions	2015025
ResistancePlus® GC Control	All platforms	10 reactions	95003

References: 1. Lahra, Monica M., Masoud Shoushtari, and Tiffany R. Hogan. "Australian Gonococcal Surveillance Programme: 1 July to 30 September 2020." *Communicable Diseases Intelligence* 44 (2020). 2. Unemo, M, et al. "WHO global antimicrobial resistance surveillance for *Neisseria gonorrhoeae* 2017–18: a retrospective observational study." *The Lancet Microbe* 2.11 (2021): e627-e636. 3. Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP 2021)" Available here: <https://www.gov.uk/government/publications/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report> 4. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. 5. Fifer, Helen, et al. "2018 UK national guideline for the management of infection with *Neisseria gonorrhoeae*." *International journal of STD & AIDS* 31.1 (2020): 4-15. 6. Unemo, Magnus, et al. "2020 European guideline for the diagnosis and treatment of gonorrhoea in adults." *International journal of STD & AIDS* (2020) 7. Allan-Blietz, Lao-Tzu, et al. "Ciprofloxacin may be efficacious in treating wild-type gyrase A genotype *Neisseria gonorrhoeae* infections." *Sexually transmitted diseases* 45.4 (2018): e18. 8. Trembizki, Ella, et al. "Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin." *The Lancet Infectious Diseases* 16.9 (2016): 1005-1006. 9. Allan-Blietz, Lao-Tzu, et al. "Ciprofloxacin may be efficacious in treating wild-type gyrase A genotype *Neisseria gonorrhoeae* infections." *Sexually transmitted diseases* 45.4 (2018): e18. 10. **ResistancePlus® GC** Instructions for use. 11. Tan, Lit Yeen, et al. "Superior multiplexing capacity of PlexPrimers enables sensitive and specific detection of SNPs and clustered mutations in qPCR." *PLoS One* 12.1 (2017): e0170087.

ResistancePlus® GC kits are developed and manufactured by **SpeedX Pty Ltd**, Sydney. **PlexPCR®** & **ResistancePlus®** are trademarks of **SpeedX Pty Ltd**. Other copyright and trademarks are the property of the respective owners. **SpeedX Pty Ltd** products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Australia - **SpeedX Pty. Ltd.**

+61 (0)2 9209 4170
sales@speedx.com.au

Suite 102, 4 Cornwallis Street,
Eveleigh NSW 2015 Australia

Europe - **SpeedX Ltd.**

+44 (0)330 445 0036
sales.uk@speedx.com.au

Acre House 11/15 William Road
London NW1 3ER United Kingdom

Demonstrated clinical performance¹⁰

	GC Detection	<i>gyrA</i> Detection
Sensitivity	96.9%	100%
Specificity	99.7%	98.6%

Validated for urine, swabs (anal, rectal, vaginal, and pharyngeal) and extracts.¹⁰

- ▶ Dual target, single-well test solution, suitable for confirming GC positives or for upfront testing with simultaneous resistance status
- ▶ Help preserve last-line antibiotics when identifying ciprofloxacin as an alternative treatment pathway
- ▶ Easily obtain ciprofloxacin susceptibility data on a range of specimen types